These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 22630170)

  • 1. Evaluation of expression and function of vascular endothelial growth factor receptor 2, platelet derived growth factor receptors-alpha and -beta, KIT, and RET in canine apocrine gland anal sac adenocarcinoma and thyroid carcinoma.
    Urie BK; Russell DS; Kisseberth WC; London CA
    BMC Vet Res; 2012 May; 8():67. PubMed ID: 22630170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of toceranib for treatment of apocrine gland anal sac adenocarcinoma in dogs.
    Heaton CM; Fernandes AFA; Jark PC; Pan X
    J Vet Intern Med; 2020 Mar; 34(2):873-881. PubMed ID: 31977135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours.
    London C; Mathie T; Stingle N; Clifford C; Haney S; Klein MK; Beaver L; Vickery K; Vail DM; Hershey B; Ettinger S; Vaughan A; Alvarez F; Hillman L; Kiselow M; Thamm D; Higginbotham ML; Gauthier M; Krick E; Phillips B; Ladue T; Jones P; Bryan J; Gill V; Novasad A; Fulton L; Carreras J; McNeill C; Henry C; Gillings S
    Vet Comp Oncol; 2012 Sep; 10(3):194-205. PubMed ID: 22236194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PDGFR-α, PDGFR-β, VEGFR-2 and CD117 expression in canine mammary tumours and evaluation of the in vitro effects of toceranib phosphate in neoplastic mammary cell lines.
    Gattino F; Maniscalco L; Iussich S; Biasato I; Martano M; Morello E; Gola C; Millán Ruiz Y; Saeki N; Buracco P; Martín de Las Mulas J; De Maria R
    Vet Rec; 2018 Aug; 183(7):221. PubMed ID: 29440590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receptor tyrosine kinase expression and phosphorylation in canine nasal carcinoma.
    Hocker SE; Higginbotham ML; Schermerhorn T; Henningson J
    Res Vet Sci; 2017 Dec; 115():484-489. PubMed ID: 28783596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression of prostaglandin EP4 receptor in three canine carcinomas.
    Musser ML; Viall AK; Phillips RL; Hostetter JM; Johannes CM
    BMC Vet Res; 2020 Jun; 16(1):213. PubMed ID: 32571310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of human epidermal growth factor receptor 2 overexpression in canine anal sac gland carcinoma.
    Yoshimoto S; Kato D; Kamoto S; Yamamoto K; Tsuboi M; Shinada M; Ikeda N; Tanaka Y; Yoshitake R; Eto S; Saeki K; Chambers JK; Kinoshita R; Uchida K; Nishimura R; Nakagawa T
    J Vet Med Sci; 2019 Jul; 81(7):1034-1039. PubMed ID: 31142682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of receptor tyrosine kinase activation and biological activity of toceranib phosphate in canine urothelial carcinoma cell lines.
    Korec DI; Louke DS; Breitbach JT; Geisler JA; Husbands BD; Fenger JM
    BMC Vet Res; 2021 Oct; 17(1):320. PubMed ID: 34600548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical analysis of expression of VEGFR2, KIT, PDGFR-β, and CDK4 in canine urothelial carcinoma.
    Setyo LC; Donahoe SL; Shearer PL; Wang P; Krockenberger MB
    J Vet Diagn Invest; 2023 Mar; 35(2):109-115. PubMed ID: 36648148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.
    Locati LD; Perrone F; Cortelazzi B; Bergamini C; Bossi P; Civelli E; Morosi C; Lo Vullo S; Imbimbo M; Quattrone P; Dagrada GP; Granata R; Resteghini C; Mirabile A; Alfieri S; Orlandi E; Mariani L; Saibene G; Pilotti S; Licitra L
    Eur J Cancer; 2016 Dec; 69():158-165. PubMed ID: 27821319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of PDGFR-β and Kit in canine anal sac apocrine gland adenocarcinoma using tissue immunohistochemistry.
    Brown RJ; Newman SJ; Durtschi DC; Leblanc AK
    Vet Comp Oncol; 2012 Mar; 10(1):74-9. PubMed ID: 22235855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of receptor tyrosine kinase targets PDGFR-β, VEGFR2 and KIT in canine transitional cell carcinoma.
    Walters L; Martin O; Price J; Sula MM
    Vet Comp Oncol; 2018 Mar; 16(1):E117-E122. PubMed ID: 28884928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of RET mutations on the expression of tyrosine kinases in medullary thyroid carcinoma.
    Rodríguez-Antona C; Muñoz-Repeto I; Inglada-Pérez L; de Cubas AA; Mancikova V; Cañamero M; Maliszewska A; Gómez A; Letón R; Leandro-García LJ; Comino-Méndez I; Sanchez L; Alvarez-Escolá C; Aller J; Cascón A; Robledo M
    Endocr Relat Cancer; 2013 Aug; 20(4):611-9. PubMed ID: 23780998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The three receptor tyrosine kinases c-KIT, VEGFR2 and PDGFRα, closely spaced at 4q12, show increased protein expression in triple-negative breast cancer.
    Jansson S; Bendahl PO; Grabau DA; Falck AK; Fernö M; Aaltonen K; Rydén L
    PLoS One; 2014; 9(7):e102176. PubMed ID: 25025175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A canine case of malignant melanoma carrying a KIT c.1725_1733del mutation treated with toceranib: a case report and in vitro analysis.
    Tani H; Miyamoto R; Noguchi S; Kurita S; Nagashima T; Michishita M; Yayoshi N; Tamura K; Bonkobara M
    BMC Vet Res; 2021 Apr; 17(1):147. PubMed ID: 33827546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of platelet-derived growth factor receptor-α/ß, vascular endothelial growth factor receptor-2, c-Abl, and c-Kit in canine granulomatous meningoencephalitis and necrotizing encephalitis.
    Song JH; Yu DH; Hwang TS; Seung BJ; Sur JH; Kim YJ; Jung DI
    Vet Med Sci; 2020 Nov; 6(4):965-974. PubMed ID: 32585777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of toceranib phosphate (Palladia) monotherapy on multidrug resistant lymphoma in dogs.
    Yamazaki H; Miura N; Lai YC; Takahashi M; Goto-Koshino Y; Yasuyuki M; Nakaichi M; Tsujimoto H; Setoguchi A; Endo Y
    J Vet Med Sci; 2017 Jul; 79(7):1225-1229. PubMed ID: 28592719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunolabelling of c-KIT and CAM5.2 in Canine Anal Sac Gland Adenocarcinoma.
    İpek E; Epikmen ET; Tunca R
    J Comp Pathol; 2022 Oct; 198():56-61. PubMed ID: 36116891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of postoperative adjuvant treatment using toceranib phosphate against adenocarcinoma in dogs.
    Yamazaki H; Tanaka T; Mie K; Nishida H; Miura N; Akiyoshi H
    J Vet Intern Med; 2020 May; 34(3):1272-1281. PubMed ID: 32267594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary evaluation of serial (18) FDG-PET/CT to assess response to toceranib phosphate therapy in canine cancer.
    Leblanc AK; Miller AN; Galyon GD; Moyers TD; Long MJ; Stuckey AC; Wall JS; Morandi F
    Vet Radiol Ultrasound; 2012; 53(3):348-57. PubMed ID: 22360684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.